NCT00816595View on ClinicalTrials.gov

Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

November 29, 2016

Conditions
LeukemiaLymphoma
Interventions
BIOLOGICAL

bevacizumab

Given IV

BIOLOGICAL

pegfilgrastim

Given subcutaneously

BIOLOGICAL

rituximab

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

pentostatin

Given IV

Trial Locations (2)

55905

Mayo Clinic, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00816595 - Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Biotech Hunter | Biotech Hunter